Paxman AB (publ) (PAX.ST)
SEK 65.0
(0.0%)
SEK 65.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 13.57 Million SEK | -20.11% |
| 2022 | 16.98 Million SEK | -0.99% |
| 2021 | 17.15 Million SEK | -64.43% |
| 2020 | 48.23 Million SEK | 53.34% |
| 2019 | 31.45 Million SEK | 146.2% |
| 2018 | 12.77 Million SEK | 362.86% |
| 2017 | 2.76 Million SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 17.19 Million SEK | 26.68% |
| 2024 Q2 | 13.33 Million SEK | -22.41% |
| 2023 Q4 | 13.57 Million SEK | -27.57% |
| 2023 Q3 | 18.73 Million SEK | 10.94% |
| 2023 FY | 13.57 Million SEK | -20.11% |
| 2023 Q1 | 16.33 Million SEK | -3.82% |
| 2023 Q2 | 16.88 Million SEK | 3.37% |
| 2022 Q3 | 19.75 Million SEK | 43.95% |
| 2022 FY | 16.98 Million SEK | -0.99% |
| 2022 Q1 | 15.71 Million SEK | -8.37% |
| 2022 Q4 | 16.98 Million SEK | -14.01% |
| 2022 Q2 | 13.72 Million SEK | -12.71% |
| 2021 Q3 | 36.3 Million SEK | -6.47% |
| 2021 Q4 | 17.15 Million SEK | -52.75% |
| 2021 FY | 17.15 Million SEK | -64.43% |
| 2021 Q1 | 36.71 Million SEK | -23.88% |
| 2021 Q2 | 38.81 Million SEK | 5.72% |
| 2020 FY | 48.23 Million SEK | 53.34% |
| 2020 Q3 | 47.98 Million SEK | 11.12% |
| 2020 Q4 | 48.23 Million SEK | 0.51% |
| 2020 Q2 | 43.18 Million SEK | 17.89% |
| 2020 Q1 | 36.63 Million SEK | 16.46% |
| 2019 Q4 | 31.45 Million SEK | 11.79% |
| 2019 Q3 | 28.13 Million SEK | 19.3% |
| 2019 Q1 | 18.71 Million SEK | 46.52% |
| 2019 FY | 31.45 Million SEK | 146.2% |
| 2019 Q2 | 23.58 Million SEK | 26.0% |
| 2018 Q3 | 8.51 Million SEK | 50.49% |
| 2018 FY | 12.77 Million SEK | 362.86% |
| 2018 Q1 | 4.3 Million SEK | 56.12% |
| 2018 Q4 | 12.77 Million SEK | 50.12% |
| 2018 Q2 | 5.65 Million SEK | 31.24% |
| 2017 FY | 2.76 Million SEK | 0.0% |
| 2017 Q2 | 2.65 Million SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q4 | 2.76 Million SEK | -18.7% |
| 2017 Q3 | 3.39 Million SEK | 27.92% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | -Infinity% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 99.159% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 99.159% |
| Arcoma AB | 3.87 Million SEK | -250.374% |
| Bactiguard Holding AB (publ) | 233.09 Million SEK | 94.178% |
| BICO Group AB (publ) | 1.85 Billion SEK | 99.268% |
| Boule Diagnostics AB (publ) | 166.1 Million SEK | 91.83% |
| CellaVision AB (publ) | 64.7 Million SEK | 79.027% |
| Clinical Laserthermia Systems AB (publ) | 454 Thousand SEK | -2888.987% |
| Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
| C-Rad AB (publ) | 1.8 Million SEK | -653.889% |
| Duearity AB (publ) | 10.58 Million SEK | -28.237% |
| Dignitana AB (publ) | 19.1 Million SEK | 28.968% |
| Episurf Medical AB (publ) | 5.2 Million SEK | -160.962% |
| Getinge AB (publ) | 8.07 Billion SEK | 99.832% |
| Scandinavian Real Heart AB (Publ) | 8.24 Million SEK | -64.492% |
| Iconovo AB (publ) | 7.72 Million SEK | -75.665% |
| Integrum AB (publ) | 6.42 Million SEK | -111.233% |
| Luxbright AB (publ) | 206.02 Thousand SEK | -6486.611% |
| Mentice AB (publ) | 9.55 Million SEK | -41.99% |
| OssDsign AB (publ) | 3.15 Million SEK | -330.794% |
| Promimic AB (publ) | - SEK | -Infinity% |
| Qlife Holding AB (publ) | 20.73 Million SEK | 34.542% |
| SciBase Holding AB (publ) | 6.79 Million SEK | -99.647% |
| ScandiDos AB (publ) | - SEK | -Infinity% |
| Sectra AB (publ) | 31.78 Million SEK | 57.311% |
| Sedana Medical AB (publ) | 4.3 Million SEK | -215.142% |
| Senzime AB (publ) | 11.46 Million SEK | -18.329% |
| SpectraCure AB (publ) | 6.71 Million SEK | -102.025% |
| Stille AB | 62.94 Million SEK | 78.44% |
| Vitrolife AB (publ) | 2.08 Billion SEK | 99.35% |
| Xvivo Perfusion AB (publ) | 31.43 Million SEK | 56.834% |